Study of IL28B gene variation as a predictor of response to directly acting antiviral therapy in hepatic transplantation hepatitis C Egyptian patients

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
H M Badawy ◽  
S S Taha ◽  
Y O Abdelrahman ◽  
S H Gadallah ◽  
R Samir ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Il28b Genotype ◽  
Donor Liver Transplantation ◽  
Gene Variation ◽  
Significant Difference ◽  
Group 2 ◽  
Group B ◽  
Group 1

Abstract Background IL28B gene polymorphisms are associated with the response to antiviral therapy in hepatitis C patients in the non-transplant setting. Objective To determine the prevalence and impact on clinical outcomes of donor and recipient IL28B genotypes among liver transplant recipients receiving directly acting antiviral therapy compared to those of HCV non-transplant patients. Patient and Methods This study included 60 patients divided into 2 groups: group 1 included 30 patients subjected to living donor liver transplantation and group 2 included 30 patients of HCV infection. Each group was subdivided into group A and group B according to the regimen of directly acting antiviral therapy (sofosbuvir-ledibasvir, sofosbuvir-daclatasvir). Liver transplantation was done between January 2016 and April 2018. Genotyping of the polymorphism was performed on DNA collected from all donors and recipients in group 1 before and after liver transplantation and also collected from all patients of group 2. Sustained virological response was found in 28 patients in group 1 (transplanted group) and 29 patients in group 2 (non-transplanted group) with no significant difference. Results No significant difference also was found in both groups according to the type of regimen. Also the type of genotype CC, CT and TT of IL28B in donors and recipients were not significantly associated or affecting the results of SVR in both groups of patients. Conclusion Our results support no role of recipient IL28B genotype in the response to directly acting antiviral drugs for hepatitis C recurrence. Interestingly, donor genotype seems not to influence the response pattern in recipients who have different IL28B genotype.

scholarly journals Congenital pes metatarsus varus: Role of arterial abnormalities in feet and treatment duration and outcome in children

2019 ◽  
Vol 147 (1-2) ◽  
pp. 65-69
Author(s):  
Dragana Cirovic ◽  
Dejan Nikolic ◽  
Tatjana Knezevic ◽  
Vesna Bokan-Mirkovic ◽  
Polina Pavicevic ◽  
...  
Keyword(s):  
Physical Therapy ◽  
Treatment Duration ◽  
Significant Difference ◽  
Group A ◽  
Group 3 ◽  
Group 2 ◽  
Group B ◽  
Prospective Longitudinal ◽  
Group 1 ◽  
Severity Degree

Introduction/Objective. The aim of this paper was to examine proportion of patients with arterial abnormalities of feet due to age and severity degree of pes metatarsus varus (PMV), and to evaluate the treatment duration and outcome. Methods. The prospective longitudinal study included 240 patients with congenital PMV classified into three age groups: group < 3 months of life (Group 1), group 3?9 months (Group 2), and group 9?12 months (Group 3). Three categories of PMV were analyzed: mild/moderate/severe. Groups with arterial anomalies (Group A) and without (Group B) were analyzed. Clinical outcome was graded as: good/satisfactory/poor. Results. There is statistically significant difference in distribution of children regarding age and severity degree on first visit and presence of feet arterial abnormalities (p < 0.01). For Group A, younger children had longer physical therapy, while for Group B, older children had longer duration of physical therapy. Same trend applies as severity degree of foot deformity increase. In Group A, the most frequent treatment outcome was poor (for Group 1 ? 46.7%; Group 2 ? 60%; Group 3 ? 62%), while in Group B for Group 1 and Group 2 it was frequently good (Group 1 ? 90%; Group 2 ? 40%), and for Group 3 frequently satisfactory (Group 3 ? 53.3%). Conclusion. In children with PMV it might be advisable to perform ultrasound evaluation of arterial structure of feet, and particularly in cases were such deformity is more severe.

scholarly journals Outcomes of liver transplantation in the era of modern antiviral therapy for hepatitis C

2021 ◽  
Vol 23 (1) ◽  
pp. 15-23
Author(s):  
K. Yu. Kokina ◽  
Yu. O. Malinovskaya ◽  
Ya. G. Moysyuk
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Antiviral Treatment ◽  
Virologic Response ◽  
Decompensated Cirrhosis ◽  
Optimal Timing ◽  
Group 2 ◽  
Direct Acting ◽  
End Stage

The emergence of direct-acting antivirals (DAAs) has become the basis for a new potential treatment for chronic hepatitis C (CHC) in patients with decompensated cirrhosis, who previously had no other alternative than liver transplantation (LT). However, optimal timing of antiviral therapy (AVT) remains an issue. Objective: to present a spectrum of clinical outcomes in LT waitlisted patients with HCV-related cirrhosis, who received and did not receive DAA therapy. Materials and methods. Enrolled for the study were 49 waitlisted patients with HCV-related end-stage liver diseases. The patients were divided into 2 groups: Group 1 included 40 patients who received DAA therapy before LT, while Group 2 consisted of 9 patients who did not receive antiviral treatment while on the LT waiting list. Results. The sample was represented in most cases by patients who had MELD/Na score <20. Only six had MELD/Na score >20, but <25. At the time of analysis, 38 patients had reached 12 weeks post AVT. Of these, 35 (92.1%) had sustained virologic response (SVR). Of these, 51.4% (n = 18) of cases showed decreased MELD/Na. There were no changes in 22.9% (n = 8). Increased MELD/Na was noted in 25.7% (n = 9). In 42.8% (n = 15) of cases, sustained elimination of HCV infection led to delisting. Among patients without SVR, increased MELD/Na was observed in all cases (n = 3). In the non-AVT group, one patient showed improved liver function (11.1%); in the rest, MELD/Na either remained stable or continued to increase - 44.5% (n = 4). A comparison of the frequency of deaths depending on AVT showed statistically significant differences (p < 0.001, V = 0.728). Among the non-AVT patients, the likelihood of waitlist death increased 66.5 times (95% CI: 7.99-554). Conclusion: DAA therapy carries significant advantages for waitlisted patients with MELD/Na score <25.

The Effect of Antiviral Therapy on Lipid Metabolism in Patients with Viral Hepatitis C

2018 ◽  
Vol 69 (8) ◽  
pp. 2025-2028
Author(s):  
Ana Simona Drochioi ◽  
Dan Cristian Moraru ◽  
Ilie Cristian Drochioi ◽  
Magdalena Iorga ◽  
Eduard Crauciuc ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Hepatitis C ◽  
Total Cholesterol ◽  
Antiviral Therapy ◽  
Cholesterol Level ◽  
Serum Cholesterol Level ◽  
Total Cholesterol Level ◽  
Viral Hepatitis C ◽  
Group 2 ◽  
Group 1

The liver is the main metabolic organ, having complex physiological and biochemical roles, many of these functions being in a close relationship. It is also well known that hepatitis C virus infection is associated with changes in lipid metabolism. This is evident in liver dysfunctions, when liver functions are disturbed simultaneously. The aim of this study is to evaluate the effect of antiviral therapy on serum lipid level in patients with viral hepatitis C before and at the end of the 48 weeks of treatment compared patients treated with Interferon vs Interferon + Ribavirin and relation with sustained virological response, from North East Romania. We evaluated patients hospitalized in Emergency Hospital for Children St. Mary Iasi between 2009-2017. The result of our study show that the mean age of patients from goup 1 was 11.85�3.65 years, vs 11.5�3.1 years in group 2 (p=0.171). We found changes in cholesterol metabolism in both groups of patients, increases in total cholesterol level, 21.43% of patients in the group 1 vs 32.3% in goup 2 (p=0.258) and decreases 17.86% vs 14.7% (p=0.131). At initiation of antiviral therapy mean serum cholesterol level were 155.78�36.30 mg/dL, in group 1 vs 149.88�47.22 mg/dL, for group 2. At 48 weeks of treatment in the both goups revealed significantly decreased of total cholesterol levels 136.46�41.63mg/dL, for group 1 vs 109.26�41.05, for patients in group 2 (p=0.003). Triglycerides, HDL cholesterol and LDL cholesterol did not show significant changes in the patients of the two groups. Total cholesterol level after antiviral therapy were significantly different between patients who achieved SVR and non SVR (p=0.014), group 1 vs (p=0.001), group 2. Total serum cholesterol level showed significant changes during the antiviral therapy in both monotherapy and combination therapy group.

In-vivo evaluation of the effect of cyanoacrylate on prosthetic vascular graft infection – does cyanoacrylate increase the severity of infection?

VASA ◽  
2020 ◽  
Vol 49 (4) ◽  
pp. 281-284
Author(s):  
Atıf Yolgosteren ◽  
Gencehan Kumtepe ◽  
Melda Payaslioglu ◽  
Cuneyt Ozakin
Keyword(s):  
Vascular Graft ◽  
Graft Infection ◽  
Vascular Graft Infection ◽  
Group 4 ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Prosthetic Vascular Graft Infection ◽  
Group 1

Summary. Background: Prosthetic vascular graft infection (PVGI) is a complication with high mortality. Cyanoacrylate (CA) is an adhesive which has been used in a number of surgical procedures. In this in-vivo study, we aimed to evaluate the relationship between PVGI and CA. Materials and methods: Thirty-two rats were equally divided into four groups. Pouch was formed on back of rats until deep fascia. In group 1, vascular graft with polyethyleneterephthalate (PET) was placed into pouch. In group 2, MRSA strain with a density of 1 ml 0.5 MacFarland was injected into pouch. In group 3, 1 cm 2 vascular graft with PET piece was placed into pouch and MRSA strain with a density of 1 ml 0.5 MacFarland was injected. In group 4, 1 cm 2 vascular graft with PET piece impregnated with N-butyl cyanoacrylate-based adhesive was placed and MRSA strain with a density of 1 ml 0.5 MacFarland was injected. All rats were scarified in 96th hour, culture samples were taken where intervention was performed and were evaluated microbiologically. Bacteria reproducing in each group were numerically evaluated based on colony-forming unit (CFU/ml) and compared by taking their average. Results: MRSA reproduction of 0 CFU/ml in group 1, of 1410 CFU/ml in group 2, of 180 200 CFU/ml in group 3 and of 625 300 CFU/ml in group 4 was present. A statistically significant difference was present between group 1 and group 4 (p < 0.01), between group 2 and group 4 (p < 0.01), between group 3 and group 4 (p < 0.05). In terms of reproduction, no statistically significant difference was found in group 1, group 2, group 3 in themselves. Conclusions: We observed that the rate of infection increased in the cyanoacyrylate group where cyanoacrylate was used. We think that surgeon should be more careful in using CA in vascular surgery.

Sign in / Sign up

Export Citation Format

Share Document